With clinical experience in emergency medicine and his specific interest in thrombosis and anti-thrombotic drugs, Dr. Pollack provides unique perspectives from clinical, research, and academic perspectives. His blogs offer insights on the most advanced approaches to thrombosis and anti-thrombotic therapy, and advancing medical education.
- For five decades, the only option for oral anticoagulation used in patients with venous thromboembolic disease and atrial fibrillation was warfarin (Coumadin®), a vitamin K antagonist originally derived from a rodenticide.1 Warfarin works by inhibiting the body’s synthesis of clotting factors that require vitamin K: Factors II, VII, IX, and X. Starting in the first …Read More »
- Because of the aging of the population and the continued success in prolonging the lifespans of patients with cardiovascular disorders such as atrial fibrillation and severe valvular disease, more and more patients—particularly among elderly cohorts—are on chronic oral anticoagulation therapy. Because of the aging of the population and the well-recognized obesity epidemic, a generally more …Read More »
- The title represents the ultimate alphabet soup, no? Most practicing physicians, however, would recognize these acronyms and have probably committed to one or the other as a preferred agent in their own patient management decisions. VKAs and NOACs are anticoagulants—that is, they prevent blood from clotting properly, which is a desirable effect in patients with or …Read More »
Follow Dr. PollackBe sure to check out Dr. Pollack’s homepage at www.charlespollackmd.com. Follow him on Twitter at @md_pollack. Stay current with his blogs on his other areas of interest in healthcare:
Questions or Comments about Thrombosis?